Adds to existing law to establish provisions regarding certain prohibited actions by pharmaceutical manufacturers.
House Bill 385 would add a new section to Idaho’s pharmacy laws to protect access to prescription drugs purchased through the federal 340B Drug Pricing Program. The bill prohibits pharmaceutical manufacturers from denying, restricting, or otherwise interfering with a covered entity’s ability to acquire 340B drugs for delivery to a contract pharmacy, and it also bars manufacturers from interfering with pharmacy contracts between covered entities and contract pharmacies.
The bill further prevents manufacturers from conditioning access to 340B drugs on the submission, validation, certification, or provision of claims, utilization, purchasing, or similar data, except for certain audits tied directly to federal 340B compliance requirements. It defines key terms such as covered entity, contract pharmacy, pharmacy, pharmaceutical manufacturer, and 340B drug, and it includes a severability clause, a federal-law compatibility clause, and a provision making the section void if the federal 340B program is eliminated.
If enacted, the bill would expand Idaho law by creating state-level restrictions on pharmaceutical manufacturers’ conduct in relation to the federal 340B program. It would affect drug manufacturers, covered entities such as eligible hospitals and clinics, and contract pharmacies that dispense 340B drugs on their behalf. The measure is designed to preserve access to discounted drugs and limit manufacturer practices that could disrupt 340B distribution arrangements, while preserving certain federally authorized audit rights and avoiding conflict with federal law.
The available record shows no committee transcript, vote tally, or recorded floor debate, so there is no direct evidence of support or opposition from the legislative process in the materials provided. Based on the bill’s sponsor and subject matter, the measure appears to be framed as a patient-access and affordability bill, suggesting a generally pro-access policy rationale. However, the absence of voting history or discussion means the overall sentiment cannot be measured beyond the bill’s text and caption.
The main likely point of contention is the scope of the restrictions on pharmaceutical manufacturers, especially the prohibition on requiring claims, utilization, or purchasing data as a condition of 340B drug access. Manufacturers may view those limits as interfering with program integrity efforts or contract terms, while covered entities and contract pharmacies are likely to support them as necessary to prevent access barriers. Another potential issue is the bill’s interaction with federal 340B law and limited distribution drugs, which the bill addresses by attempting to align with federal requirements and exempt certain federally mandated distribution restrictions.